by The global Respiratory disease vaccine market size was estimated to be around US$ 116.53 billion in 2022. It is projected to reach US$ 116.53 billion by 2032, indicating a CAGR of 2.05% from 2023 to 2032.
Key Takeaways
- Asia Pacific dominated the market in 2022 with the largest market share of 55% in 2022.
- By Distribution Channel, the hospital segment dominated the market with the highest market of 55% in 2022.
- By Disease Type, the chronic obstructive pulmonary disease (COPD) segment dominated the market in 2022.
- By Type, the viral vaccine segment contributed more than 55% of revenue share in 2022.
- By Type, the bacterial vaccine segment is expected to expand at a significant CAGR during the forecast period.
- By Age Group, the adult segment dominated the market with a major market share of 77% in 2022.
- By Age Group, the pediatric segment is expected to be the most lucrative segment of the market throughout the forecast period.
- By Infection, the COVID-19 segment captured more than 70% of market share in 2022.
- By Infection, the Respiratory Syncytial Virus (RSV) segment is expected to grow at a significant rate during the forecast period.
The market research report on the Respiratory disease vaccine market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Respiratory disease vaccine products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3249
Report Scope of the Respiratory Disease Vaccine Market:
| Report Coverage | Details |
| Market Size in 2023 | USD 97.08 Billion |
| Market Size by 2032 | USD 116.53 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 2.05% |
| Largest Market | Asia Pacific |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Disease Type, By Type, By Age Group, and By Infection, By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Chip Resistor Market Size to Garner USD 3.7 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Respiratory disease vaccine market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Respiratory disease vaccine market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Respiratory disease vaccine products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Respiratory disease vaccine market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Respiratory disease vaccine market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Respiratory disease vaccine market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Key Market Players:
- Sanofi
- GSK plc
- Merck & Co., Inc.
- Pfizer Inc.
- Bavarian Nordic
- EMERGENT
- CSL Limited
- Moderna, Inc.
- Serum Institute of India Pvt. Ltd.
- Sinovac Biotech
Segments Covered in the Report:
By Disease Type
- Chronic Obstructive Pulmonary Disease (COPD)
- Pertussis
- Pneumonia
- Measles
- Diphtheria
By Type
- Viral Vaccine
- Bacterial Vaccine
- Combination Vaccine
By Age Group
- Pediatric
- Adult
By Infection
- COVID-19
- Influenza
- Respiratory Syncytial Virus (RSV)
- Pneumonia
- Others
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Respiratory Disease Vaccine Market
5.1. COVID-19 Landscape: Respiratory Disease Vaccine Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Respiratory Disease Vaccine Market, By Disease Type
8.1. Respiratory Disease Vaccine Market Revenue and Volume, by Disease Type, 2023-2032
8.1.1. Chronic Obstructive Pulmonary Disease (COPD)
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Pertussis
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. Pneumonia
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. Measles
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. Diphtheria
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Respiratory Disease Vaccine Market, By Type
9.1. Respiratory Disease Vaccine Market Revenue and Volume, by Type, 2023-2032
9.1.1. Viral Vaccine
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Bacterial Vaccine
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
9.1.3. Combination Vaccine
9.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Respiratory Disease Vaccine Market, By Age Group
10.1. Respiratory Disease Vaccine Market Revenue and Volume, by Age Group, 2023-2032
10.1.1. Pediatric
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Adult
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Respiratory Disease Vaccine Market, By Infection
11.1. Respiratory Disease Vaccine Market Revenue and Volume, by Infection, 2023-2032
11.1.1. COVID-19
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Influenza
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
11.1.3. Respiratory Syncytial Virus (RSV)
11.1.3.1. Market Revenue and Volume Forecast (2020-2032)
11.1.4. Pneumonia
11.1.4.1. Market Revenue and Volume Forecast (2020-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Respiratory Disease Vaccine Market, By Distribution Channel
12.1. Respiratory Disease Vaccine Market Revenue and Volume, by Distribution Channel, 2023-2032
12.1.1. Hospital & Retail Pharmacies
12.1.1.1. Market Revenue and Volume Forecast (2020-2032)
12.1.2. Government Suppliers
12.1.2.1. Market Revenue and Volume Forecast (2020-2032)
12.1.3. Others
12.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 13. Global Respiratory Disease Vaccine Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.1.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.1.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.1.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.1.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.1.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.1.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.1.7.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.1.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.1.7.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.7. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.9.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.9.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.10. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.12.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.12.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.12.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.2.14.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.2.14.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.2.14.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.10.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.10.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.10.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.3.11.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.3.11.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.3.11.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.10.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.10.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.10.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.4.11.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.4.11.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.4.11.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.5.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.5.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.5.6.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.5.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.5.6.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Disease Type (2020-2032)
13.5.8.2. Market Revenue and Volume Forecast, by Type (2020-2032)
13.5.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
13.5.8.4. Market Revenue and Volume Forecast, by Infection (2020-2032)
13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Sanofi
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. GSK plc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Merck & Co., Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Pfizer Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Bavarian Nordic
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. EMERGENT
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. CSL Limited
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Moderna, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Serum Institute of India Pvt. Ltd.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Sinovac Biotech
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
